



THIS IS AN ABRIDGED PROSPECTUS CONTAINING SALIENT FEATURES OF THE PROSPECTUS. YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE PROSPECTUS. (DOWNLOAD LINK: MEDISTEPHC.COM) UNLESS OTHERWISE SPECIFIED ALL CAPITALIZED TERMS USED HEREIN AND NOT SPECIFICALLY DEFINED SHALL HAVE THE SAME MEANING AS ASCRIBED TO THEM IN THE PROSPECTUS.

**THIS ABRIDGED PROSPECTUS CONSISTS OF TEN PAGES. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.**

Fixed Price Issue



**MEDISTEP HEALTHCARE LIMITED**

**Corporate Identification Number: U21009GJ2023PLC141841**

**Date of Incorporation: June 05, 2023**

REGISTERED OFFICE	CORPORATE OFFICE	CONTACT PERSON	EMAIL & TELEPHONE	WEBSITE
05, S.NO-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, Nr. A-One Hotel, N.H.-8, Narol Gam, Narol, Ahmedabad City, Daskroi, Gujarat, India, 382405	-	Ms. Sashi kala Bhutra, Company Secretary & Compliance Officer	<a href="mailto:Info@medistephc.com">Info@medistephc.com</a> +91 87808 46963	<a href="http://www.medistephc.com">www.medistephc.com</a>

**PROMOTERS OF THE COMPANY**

***GIRDHARI LAL PRAJAPAT, DABHI VIPUL GOBARBHAI, PRAJAPATI HETALBEN GIRDHARILAL & JAGDISH PRAJAPATI***

**DETAILS OF OFFER TO PUBLIC**

Type of Issue (Fresh/OFS/ Fresh & OFS)	Fresh Issue Size (by no. of shares or by amount in Rs.)	OFS Size (by no. of shares or by amount in Rs.)	Total Issue Size (by no. of shares or by amount in `)	Issue Under 6(1) / 6(2)/ 229(1)/ 229(2) & Share Reservation amount QIB, NII, RII
Fresh Issue	37,44,000 Equity Shares at Face Value of Rs. 10 each at an offer price Rs. 43/- aggregating to Rs. 1609.92 Lakhs	NIL	37,44,000 Equity Shares aggregating to Rs. 1609.92 Lakhs	The Issue is being made pursuant to Regulation 229(2) of Chapter IX of SEBI (ICDR) Regulations 2018 as amended.  <b>Share Reservation</b>  1,89,000 equity shares reserved for subscription by Market Maker. Minimum 50% of the Net Offer is allocated for Individual Investors and the balance is offered to other investors including non-individuals.

***These equity shares are proposed to be listed on SME Platform of National Stock Exchange of India Limited i.e. NSE Emerge***

**DETAILS OF OFFER FOR SALE BY PROMOTER(S)/ PROMOTER GROUP/ OTHER SELLING SHAREHOLDERS**

**(UPTO A MAXIMUM OF 10 SELLING SHAREHOLDERS)**

Name Of Selling Shareholder	Type	Number Of Equity Shares Offered/ Amount in Rs.	Weighted Average Cost Of Acquisition (In Rs. Per Equity Share)	Their Average Cost of Acquisition (In ₹ Per Equity Share)	Name Of Selling Shareholder	Type	Number Of Equity Shares Offered/ Amount	Weighted Average Cost Of Acquisition (In ₹ Per Equity Share)
N.A.								

PRICE, MINIMUM BID LOT & INDICATIVE TIMELINES	
Fixed Price Issue*	Rs. 43 /- Per Equity Share of face value of 10/- each.
Minimum Bid Lot Size	Minimum of Two lots (One Lot size consist of 3000 equity shares each) and in multiples of 3000 shares thereafter
Bid/Offer Open On	Friday, August 08, 2025
Bid/Closes Open On	Tuesday, August 12, 2025
Finalization of Basis of Allotment	Wednesday August 13, 2025
Initiation of Refunds/ unblocking of ASBA Accounts	Thursday, August 14, 2025
Credit of Equity Shares to Demat accounts of Allottees	Thursday, August 14, 2025
Commencement of trading of Equity Shares	Monday, August 18, 2025

\*For details of Basis of Issue Price, please refer to “Basis for issue Price” page no 101 of Prospectus.

**The Weighted average cost of acquisition of all Equity Shares transacted over the trailing eighteen months from the date of Prospectus**

Name of shareholders	No. of shares Acquire in last Eighteen Months	Weighted Average Price (in Rs.)**
Ms. Prajapati Hetalben Girdharilal	31,97,600	12.50
Mr. Girdharilal Prajapat	14,11,600	12.50
Mr. Dabhi Vipul Gobarbhai	12,69,680	12.50
Ms. Nishakumari Vicky Agrawal	Nil	Nil
Mr. Agrawal Vicky Mahadev	Nil	Nil
Mr. Vishnu Kumar	Nil	Nil
Ms. Dabhi Dharmishtaben V	Nil	Nil

\*\*As certified by M/s Mukesh Mishra & Associates, Chartered Accountants, by way of their certificate dated July 31<sup>st</sup> 2025.

WACA: Weighted Average Cost of Acquisition shall be calculated on fully diluted basis for the trailing eighteen months from the date of Prospectus.

RISKS IN RELATION TO THE FIRST ISSUE
This being the first public issue of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is Rs. 10/- each and the Issue Price is 4.3 times of the face value of the Equity Shares. The Issue Price (determined and justified by our Company in consultation with the Lead Manager as stated in “Basis for Issue Price” on page no 101 of this prospectus) should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.
GENERAL RISK
Investments in Equity and Equity related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”),

nor does SEBI guarantee the accuracy or adequacy of the Prospectus. Specific attention of the investors is invited to the section “Risk Factors” beginning on page no. 30 of this Prospectus.

#### PROCEDURE



You may obtain a physical copy of the Bid-cum-Application Form and the Prospectus from the stock exchange, syndicate members, registrar to the issue, share transfer agents, depository participants, stock brokers, underwriters, bankers to the issue, investors’ associations or Self Certified Syndicate Banks.


If you wish to know about processes and procedures applicable to this issue, you may request for a copy of the Prospectus and/or the General Information Document (GID) from the Lead Manager or download it from the website of the Stock Exchange i.e. [www.nseindia.com](http://www.nseindia.com) and the LM at [www.ftfinsec.com](http://www.ftfinsec.com)

#### PRICE INFORMATION OF LM’s

Sr. No.	Issue name	Name of Merchant Banker	+/- % change in closing price, [+/- % change in closing benchmark]- 30th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 90th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 180th calendar days from listing
1.	Cedaar Textile Limited	<b>FAST TRACK FINSEC PRIVATE LIMITED</b>	NA	NA	NA
2.	Jainik Power Cables Limited		17.98	NA	NA
			1.03		
3.	Nikita papers Limited		0.55	NA	NA
			(3.40)		
4.	Gajanand International Limited		(42.60)	(50.13)	(61.40)
			(1.62)	(4.12)	13.33
5.	Ambey Laboratories Limited		(26.16)	(29.94)	(35.41)
			0.13	2.73	5.41
6.	Akiko Global Services Limited		(18.80)	(14.30)	(14.68)
		3.68	3.55	(1.29)	
7.	Enser Communications Limited	(2.99)	146.36	274.54	
		1.08	6.65	15.03	
8.	Sungarner Energies Limited	(17.66)	(27.57)	23.91	
		(0.95)	4.37	15.29	

Source: Price Information [www.bseindia.com](http://www.bseindia.com) & [www.nseindia.com](http://www.nseindia.com) Offer Information from respective Prospectus.


<b>Name of LM and contact details</b>	 <b>Fasttrack Finsec</b> <small>Category-I Merchant Banker</small> <b>FAST TRACK FINSEC PRIVATE LIMITED</b> Address: Office No. V-116, 1 <sup>st</sup> Floor, New Delhi House, 27, Barakhambha Road, New Delhi – 110 001 Tel No +91-11-43029809 Email: <a href="mailto:mb@ftfinsec.com">mb@ftfinsec.com</a> ; Contact Person: Ms. Sakshi
<b>Name of Syndicate Members</b>	Not Applicable
<b>Name of Market Makers</b>	 <b>NIRMAN SHARE BROKERS PRIVATE LIMITED</b> Address: Nirman House-8, Zone-1, M.P. Nagar Bhopal, Madhya Pradesh, India, 462011

	<p><b>Tel No.:</b> 0755-4260000  <b>Email:</b> accounts@nirmanbroking.com  <b>Website:</b> www.nirmanbroking.com  <b>Contact Person:</b> Abhishek Jain  <b>SEBI Registration No.:</b> INZ000197638</p>
<b>Name of Registrar to the Offer and contact details</b>	 <b>CAMEO</b> <b>Cameo Corporate Services Limited</b> <b>Address:</b> “Subramanian Building”, No. 1, Club house Road, Chennai-600002 <b>Tel No:</b> +91-44-40020700; <b>Fax No:</b> +91-44-28460390 <b>Email:</b> <a href="mailto:ipo@cameoindia.com">ipo@cameoindia.com</a> <b>Website:</b> <a href="http://www.cameoindia.com">www.cameoindia.com</a> <b>Contact Person:</b> Ms. K Sreepriya, Executive, Vice president <b>SEBI Registration No.:</b> INR000003753
<b>Name of Statutory Auditor</b>	<p><b>M/s Mukesh Misha &amp; Associates</b>  <b>Address:</b> 2<sup>nd</sup> Floor, Asha Tower, Kokrajhar, Assam - 783370  <b>Tel No:</b> +91-63572 51190  <b>Email:</b> cabhoomikatanejal@gmail.com  <b>Website:</b> NA  <b>Contact Person:</b> CA Bhoomika Nowlakha</p>
<b>Name of Credit Rating Agency and the rating or grading obtained if any</b>	Not Applicable
<b>Name of Debenture trustee, if any.</b>	Not Applicable
<b>Self-Certified Syndicate Banks</b>	The list of banks is available on <a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=35">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=35</a>
<b>Non-Syndicate Registered Brokers</b>	You can submit Application Forms in the Issue to Non-Syndicate Registered Brokers at the Non-Syndicate Broker Centers. For further details, see section titled “ <b>Issue Procedure</b> ” beginning at page no. 297 of the Prospectus
<b>Details regarding website address(es)/ link(s) from which the investor can obtain list of Registrar to issue and share transfer agents, depository participants and stock brokers who can accept application from investor (as applicable)</b>	<a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes</a>

<b>PROMOTERS OF THE ISSUER COMPANY</b>			
<b>Sr. No.</b>	<b>Name</b>	<b>Individual/Corporate</b>	<b>Experience &amp; Educational Qualification</b>
1	<b>Mr. Girdhari Lal Prajapat</b>	Individual	<b>Experience:</b> He possesses over 12 years of experience in the pharmaceutical industry. He began his career in the production department at Cadila Pharmaceuticals and advanced through various roles in sales and marketing as an apprentice trainee. Additionally, he was also associated with AIMS Hospital, Paldi, Ahmedabad, as a pharmacist. Mr. Prajapat oversees business expansion and overall management of the company.

			<b>Qualification:</b> Bachelor in pharmacy
2	<b>Mrs. Prajapati Hetalben Girdharilal</b>	Individual	<p><b>Experience:</b> She possess over six years of experience in the pharmaceutical industry, with expertise in sales, inventory management, and market operations. She began her career as a Sales Executive at Nand Kishor Medical and General Store (2014–2016), where she gained in-depth product knowledge and customer management skills. She later started her own proprietorship firm, MG Pharma, which got acquired by Medistep Healthcare Limited. Currently, she is a Non-Executive Director on the Board of Medistep Healthcare Limited, contributing her industry insights and operational experience to the company’s strategic growth.</p> <p><b>Qualification:</b> 9<sup>th</sup> pass</p>
3	<b>Mr. Dabhi Vipul Gobarbhai</b>	Individual	<p><b>Experience:</b> He possess over 19 years of experience in hospital practice. Dr. Dabhi was associated with several renowned healthcare institutions, including Hope Neurocare, Rudraksh Institute of Medical Science, and Narol ICU and Trauma Center in Ahmedabad.</p> <p><b>Qualification:</b> B.A.M.S</p>
4	<b>Mr. Jagdish Prajapati</b>	Individual	<p><b>Experience:</b> Mr. Jagdish Prajapati possess over 6 years of experience and has associated with Virtual Accounting Solutions LLP and Lalit K Sharma &amp; Company, and A &amp; D Consulting Inc. His expertise in financial management and corporate governance makes him a key contributor to the company's growth.</p> <p><b>Qualification:</b> C.A (Inter), B.com.</p>

<b>BUSINESS OVERVIEW AND STRATEGY</b>					
<b>Company Overview</b>	The company operates in the pharmaceutical industry and is involved in the business of trading of pharmaceutical products, intimate care and hygiene products, surgical products & nutraceutical products and manufacturing of intimate and nutraceutical products. For further details, please see “Our Business” on page no. 139				
<b>Product /Service Offering</b>	Pharmaceutical products, intimate care and hygiene products, surgical products & nutraceutical products and manufacturing of intimate and nutraceutical products and Other Related Products.				
<b>Revenue segmentation by product/ Service offering</b>	<b>S. No.</b>	<b>Particulars</b>	<b>For the Year as on</b>		
			<b>March 31, 2025 (Rs. in Lakhs)</b>	<b>March 31, 2024 (Rs. in Lakhs)</b>	<b>March 31, 2023 (Rs. in Lakhs)</b>
	1.	Intimate Care & Hygeine Products (Drystep Sanitary Pad)	1,110.64	103.38	0
	2.	Nutraceuticals Products (Vitastep-Z Energy Powder)	205.53	22.63	0
		<b>Total (A)</b>	1316.17	126.01	0
	3.	Intimate Care & Hygeine Products	3532.25	3,397.21	425.59
	4.	Pharmaceuticals Products	42.83	301.20	168.77
	5.	Nutraceuticals	69.25	3.77	20.61

		Products				
	6.	Surgical Products & Instruments	4.49	75.20	2,147.53	
	7.	Over the Counter (OTC) Products	0.49	3.80	2.18	
		<b>Total (B)</b>	3,649.31	3781.18	2764.68	
		<b>Total (A+B)</b>	4,965.48	3907.19	2764.68	
<b>Geographies Served</b>	Gujarat and Rajasthan					
<b>Revenue segmentation by geographies</b>	<b>S. No.</b>	<b>Particulars</b>	<b>For the Year as on</b>			
			<b>March 31, 2025 (Rs. in Lakhs)</b>	<b>March 31, 2024 (Rs. in Lakhs)</b>	<b>March 31, 2023 (Rs. in Lakhs)</b>	
	1.	Gujarat	4,965.48	3,905.79	2,763.14	
2.	Rajasthan	0.00	1.40	1.53		
<b>Key Performance Indicators</b>	Key financial and operational performance indicators of our Company, as included in “ <i>Basis for Issue Price</i> ” beginning on page no. 101 of the Prospectus.					
<b>Client Profile of Industries Served</b>	Pharma Industry					
<b>Revenue segmentation in terms of top 5/10 clients or Industries</b>	Our top ten customers have contributed 89.93%, 68.36% and 97.30% of our revenues for the March 31, 2025, March 31, 2024, and March 31, 2023 based on Restated Financial Statements.					
<b>Intellectual Property</b>	<b>S. No.</b>	<b>Trademark / Wordmark</b>	<b>Date of application</b>	<b>Application number</b>	<b>Class</b>	<b>Current Status</b>
	1.	Medistep	18.09.2023	6114795	5	Opposed
	2.	 MEDISTEP HEALTHCARE LTD.	18.09.2023	6114798	5	Objected
<b>Market Share</b>	No Data Available.					
<b>Manufacturing Plant</b>	Survey No. 298, Near Radio Station, Bidaj Gam, Bareja, Kheda, Gujarat – 387120					
<b>Employee, Strength:</b>	As on July 20, 2025, the Company has employed 9 employees at various levels of the Organization.					

#### BOARD OF DIRECTORS

Sr. No.	Name	Designation (Independent / Whole time / Executive / Nominee)	Experience & Educational Qualification	Other Directorships

1.	<b>Mr. Girdhari Lal Prajapat</b>	Managing Director	<p><b>Experience:</b> He possesses over 12 years of experience in the pharmaceutical industry. He began his career in the production department at Cadila Pharmaceuticals and advanced through various roles in sales and marketing as an apprentice trainee. Additionally, he was also associated with AIMS Hospital, Paldi, Ahmedabad, as a pharmacist. Mr. Prajapat oversees business expansion and overall management of the company.</p> <p><b>Qualification:</b> Bachelor in Pharmacy from Rajasthan University of Health Sciences, Jaipur</p>	<p><b>INDIAN COMPANIES: Nil</b></p> <p><b>FOREIGN COMPANIES: Nil</b></p>
2.	<b>Mrs. Prajapati Hetalben Girdharilal</b>	Non-Executive Director	<p><b>Experience:</b> She possess over six years of experience in the pharmaceutical industry, with expertise in sales, inventory management, and market operations. She began her career as a Sales Executive at Nand Kishor Medical and General Store (2014–2016), where she gained in-depth product knowledge and customer management skills. She later started her own proprietorship firm, MG Pharma, which got acquired by Medistep Healthcare Limited. Currently, she is a Non-Executive Director on the Board of Medistep Healthcare Limited, contributing her industry insights and operational experience to the company’s strategic growth.</p> <p><b>Qualification:</b> 9th Pass</p>	<p><b>INDIAN COMPANIES: Nil</b></p> <p><b>FOREIGN COMPANIES: Nil</b></p>
3.	<b>Mr. Dabhi Vipul Gobarbhai</b>	Executive Director	<p><b>Experience:</b> He has over 19 years of experience in hospital practice. Dr. Dabhi was associated with several renowned healthcare institutions, including Hope Neurocare, Rudraksh Institute of Medical Science, and Narol ICU and Trauma Center in Ahmedabad.</p> <p><b>Qualification:</b> B.A.M.S from Gujarat Ayurved University</p>	<p><b>INDIAN COMPANIES: Nil</b></p> <p><b>FOREIGN COMPANIES: Nil</b></p>
4.	<b>Mr Dodiya Kapilbhai Raysinhbhai</b>	Non-Executive and Independent Director	<p><b>Experience:</b> He has 8 years of diverse experience in the hospital and healthcare sector. Since 2017, He has been the Partner of Jeevandeep Hospital in Matar, Kheda, Gujarat, where he has been pivotal in elevating the hospital's standards and reputation. During the COVID-19 pandemic, he played a crucial role in providing hospital-based and community-level care. He also serves as the Partner of Shree Krishna Multispeciality Hospital, Bareja, Ahmedabad, where he leads the development of policies and procedures.</p>	<p><b>INDIAN COMPANIES: Nil</b></p> <p><b>FOREIGN COMPANIES: Nil</b></p>

			<b>Qualification:</b> B.H.M.S. from Hemchandracharya North Gujarat, University Patan	
5.	<b>Mr. Khoda Anandbhai Jitendrabhai</b>	Non-Executive and Independent Director	<b>Experience:</b> He has over 15 years of experience in the healthcare sector. He has been associated with prestigious institutions such as Tower Hospital, Jafarabad, Amreli, and, Iskon, Ahmedabad and he is the director of Rudra Rudra Super Speciality Hospital Private Limited. For the past six years, he has served as the Partner of Astha Hospital, Bareja, Ahmedabad, where his leadership has significantly elevated the hospital's performance and reputation.  <b>Qualification:</b> B.H.M.S. from Vikram University, Ujjain, MP	<b>INDIAN COMPANIES:</b> 1. Rudra Super Speciality Hospital Private Limited  <b>FOREIGN COMPANIES:</b> <b>Nil</b>

For further details in relation to our Board of Directors, see “**Our Management**” beginning on page no.184of the Prospectus.

### OBJECT OF THE OFFER

#### Details of means of finance –

The fund requirements for each of the objects of the Issue are stated as follows:

Sr. No.	Objects of the Issue	Amount (In Rs. Lakh)
1.	Funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility	50.75
2.	Working Capital Requirement	1234.17
3.	General Corporate Purpose; and	193.00
4.	Issue Expenses	132.00
5.	<b>Total</b>	<b>1609.92</b>

*\*M/s Mukesh Mishra & Co., Chartered Accountants (Peer reviewed Statutory Auditor of the Company) vide certificate dated July 31<sup>st</sup> 2025 has certified that the Company has incurred expenses of Rs. 24.56 Lakh towards “Issue Expenses” as on July 22, 2025 from its internal accruals*

**Note:-** The amount to be utilized for general corporate purposes shall not exceed 15% or 10 crores, whichever is lower, of the gross proceeds from the Fresh Issue.

**Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues / rights issue, if any, of the Company in the preceding 10 years: Nil**

**Name of monitoring agency, if any: NA**

**Terms of Issuance of Convertible Security, if any: Not Applicable**

SHAREHOLDING PATTERN			
Sr. No.	Particulars	Pre-Issue number of shares	% Holding of Pre issue
1.	Promoter and Promoter Group	97,98,280	93.62%
2.	Public	6,67,266	6.38%
	<b>Total</b>	<b>104,65,546</b>	<b>100.00%</b>

**Number/amount of equity shares proposed to be sold by selling shareholders. – Not Applicable.**

#### RESTATED FINANCIALS STATEMENT:

(All amounts in Indian Rupees in Lakhs, unless otherwise stated)

Particulars	March 31, 2025	March 31, 2024	March 31, 2023
<b>Total income from operations</b>	4,965.48	3,907.19	2,764.68
<b>Net Profit/(Loss) before tax and</b>	553.87	444.641	123.07



<b>extraordinary items</b>			
<b>Net Profit / (Loss) after tax and extraordinary items</b>	414.42	332.75	92.10
<b>Equity Share Capital</b>	1046.55	632.07	107.24
<b>Reserves and Surplus</b>	636.92	679.11	-
<b>Net Worth (1)</b>	1683.47	1311.17	107.24
<b>Restated Basic Earnings per Share (2)</b>	4.01	19.96	-
<b>Restated Diluted Earnings per Share (3)</b>	4.01	19.96	-
<b>Restated Net Asset Value per Share (4) (Post Bonus)</b>	16.09	11.93	-
<b>Total Borrowings (5)</b>	63.53	71.79	53.24

- (1) Net Worth is calculated as the sum of equity share capital and other equity attributable to owners of the Company;
- (2) Basic EPS = Net Profit after tax, as restated, attributable to equity shareholders divided by weighted average no. of equity shares outstanding during the year/ period
- (3) Diluted EPS = Net Profit after tax, as restated, attributable to equity shareholders divided by weighted average no. of diluted equity shares outstanding during the year/ period.
- (4) Net Asset Value per share = Net worth attributable to the owners of the company divided by the numbers of shares outstanding as at year end.
- (5) Total borrowings is the sum of short-term borrowings and long-term borrowings

#### **INTERNAL RISK FACTORS**

**(Minimum 5 and maximum 10 risk factors to be specified)**

**The below mentioned risks are top 7 risk factors as per the Prospectus**

- Expanding the company's business focus from trading pharmaceuticals to manufacturing sanitary pads, energy powders, and multivitamins introduces several inherent risk factors that must be carefully evaluated.
- We provide our goods majorly in Gujarat, any adverse changes in the conditions affecting these regions can adversely affect our business, financial condition and results of operations.
- We rely on domestic third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect our business, results of operations, financial condition and cash flows.
- Our manufacturing facility are subject to operational risks. Any slowdown or shutdown in our manufacturing operations could adversely affect our business, financial condition and results of operations.
- The Company is dependent on few numbers of customers for sales. The loss of any of this large customer may affect our revenues and profitability.
- We are subject to extensive government regulations and if we fail to obtain, maintain or renew our statutory and regulatory licenses, permits and approvals required to operate our business, our business, financial condition, results of operations and cash flows may be adversely affected.
- Any increase in the cost of our raw material or other purchases or a shortfall in the supply of our raw materials, may adversely affect the pricing and supply of our products and have an adverse effect on our business, results of operations and financial condition.

For further details on "**Risk Factors**" please refer page no. 30 of the Prospectus.

#### **SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION**

##### **A. Total number of outstanding litigations against the company and amount involved**

(Rs. in lakhs)

Sr. No.	Name of individual/ entity	Criminal Proceedings	Tax proceedings	Statutory/ Regulatory proceeding	Disciplinary actions by the SEBI or stock Exchanges against our Promoters	Material civil litigation	Aggregate amount involved
1.	<b>Company</b>						

	By the Company	Nil	Nil	Nil	Nil	Nil	Nil
	Against the Company	Nil	Nil	Nil	Nil	Nil	Nil
2.	<b>Directors (Other than Promoters)</b>						
	By the Directors	Nil	Nil	Nil	Nil	Nil	Nil
	Against the Directors	Nil	Nil	Nil	Nil	Nil	Nil
3.	<b>Promoters</b>						
	By the Promoters	Nil	Nil	Nil	Nil	Nil	Nil
	Against the Promoters	Nil	Nil	Nil	Nil	Nil	Nil
4.	<b>Subsidiaries</b>						
	By the Subsidiaries	Not Applicable					
	Against the Subsidiaries						
5.	<b>Group Companies</b>						
	By the Group Companies	Nil	Nil	Nil	Nil	Nil	Nil
	Against the Group Companies	Nil	Nil	Nil	Nil	Nil	Nil
6.	<b>KMP</b>						
	By the KMP	Nil	Nil	Nil	Nil	Nil	Nil
	Against the KMP	Nil	Nil	Nil	Nil	Nil	Nil

For further details, see “**Outstanding Litigation and Material Developments**” on page no. 265 of the Prospectus.

- B. Brief details of top 5 material outstanding litigations against the company and amount involved - NIL**
- C. Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any - NIL**
- D. Brief details of outstanding criminal proceedings against Promoters (200- 300-word limit in total) – NIL**

<b>ANY OTHER IMPORTANT INFORMATION AS PER LM / ISSUER COMPANY</b>
NIL
<b>DECLARATION BY THE COMPANY</b>
We hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, and the regulations or guidelines issued by Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992 as the case may be, have been complied with and no statement made in this Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, and the Securities and Exchange Board of India Act, 1992, each as amended or the rules, regulations or guidelines issued thereunder, as the case may be. I further certify that all the disclosures and statements made in this Prospectus are true and correct.

**THIS PAGE IS INTENTIONALLY LEFT BLANK**